 49 PM / Updated 24 minutes ago BRIEF-Adverum Biotechnologies Provides 2018 Outlook Reuters Staff 
Jan 4 (Reuters) - Adverum Biotechnologies Inc: * ADVERUM BIOTECHNOLOGIES PROVIDES 2018 OUTLOOK 
* ADVERUM BIOTECHNOLOGIES INC - ADVERUMâ€˜S CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $186.6 MILLION AS OF SEPTEMBER 30, 2017. 
* ADVERUM BIOTECHNOLOGIES INC - CURRENT CASH POSITION IS EXPECTED TO FUND THREE LEAD GENE THERAPY PROGRAMS THROUGH END OF 2019 
* ADVERUM - PLAN TO SUBMIT 2 INVESTIGATIONAL NDA WITH FDA IN H2 2018, FOR ADVM-022 IN WET AMD, ADVM-053 IN HEREDITARY ANGIOEDEMA Source text for Eikon: Further company coverage: